Prostate News Archive
28-Jan-2011
Avodart Gets Rejected By FDA For Reducing Prostate Cancer Risk
The Food and Drug Administration is not willing to expand the approval of an existing drug for enlarged prostates as a means to reduce the risk of prostate cancer. A panel of expert previously recommended against the expansion. FDA Denies Glaxo Prostate Drug
U.S. health regulators have declined to approve GlaxoSmithKline's Avodart enlarged prostate drug for reducing the risk of prostate cancer in men deemed to be at increased risk Prostate-shrinking drug may help detect cancer
Study finds that men who used medication received more accurate readings on their prostate specific antigen tests.
Back to Prostate News Archive
